Physician profile
Monica Young
NPI 1033107552
$2,684.53
in general payments reported to CMS, 2019-2025
22 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $454 · 2021: $324 · 2022: $396 · 2023: $355 · 2024: $330 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.79 | 2019-2025 | Vraylar |
| Allergan, INC. | $273.86 | 2019-2020 | |
| Novo Nordisk INC | $239.08 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $228.04 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $223.38 | 2020-2025 | Airsupra, Breztri |
| Nestle Healthcare Nutrition INC. | $203.76 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $189.68 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.38 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $88.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.07 | 2021-2025 | |
| Pfizer INC. | $73.72 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.22 | 2025 | Caplyta |
| Astellas Pharma US INC | $58.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $53.39 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $52.83 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.70 | 2019-2021 | |
| Axsome Therapeutics, INC. | $46.04 | 2023-2024 | Auvelity |
| Lundbeck LLC | $45.35 | 2025 | Rexulti |
| Amarin Pharma, INC. | $42.84 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $39.20 | 2025 | Rexulti |
| Lilly USA, LLC | $32.31 | 2023-2024 | Mounjaro, Emgality, Jardiance |
| Insulet Corporation | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.